Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38- subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV

Gene Therapy

Volumn 7, Issue 3, 2000, Pages 183-195

  Nathwani, A C ^a   Hanawa, H ^a   Vandergriff, J ^a   Kelly, P ^a   Vanin, E F ^a   Nienhuis, A W ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Gene therapy; Hematopoietic progenitor; Stem cell; Transient expression

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN; CYTOKINE; DIHYDROFOLATE REDUCTASE; GREEN FLUORESCENT PROTEIN; TRIMETREXATE; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ARTICLE; COLONY FORMATION; CONTROLLED STUDY; ECOTROPIC VIRUS; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HELPER VIRUS; HUMAN; HUMAN CELL; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; UMBILICAL CORD BLOOD; VIRUS RECOMBINANT;

EID: 0033995253     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301068     Document Type: Article

References (62)

1. Hawley RG, Fong AZ, Burns BF, Hawley TS. Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus. J Exp Med 1992; 176: 1149-1163.
2. Persons DA et al. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood 1997; 90: 1777-1786.
3. Brenner MK et al. Gene marking to determine whether autologous marrow infusion restores long-term haematopoiesis in cancer patients. Lancet 1993; 342: 1134-1137.
4. + bone marrow cells. Blood 1993; 82: 1975-1980.
5. Dunbar CE et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85: 3057-3084.
6. Orlic D et al. The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction. Proc Natl Acad Sci USA 1996; 93: 11097-11102.
7. Sorrentino BP, Nienhuis AW. The hematopoietic system as a target for gene therapy. In: Friedmann T (ed). The Development of Gene Therapy. Cold Spring Harbor Laboratory Press: New York, 1998, pp 351-354.
8. Nienhuis AW et al. Gene transfer into hematopoietic cells. Stem Cells 1997; 15: 123-124.
9. + human hematopoietic progenitor cells after transduction. Blood 1996; 88: 492-504.
10. Goodman S et al. Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells. Blood 1994; 84: 1492-1500.
11. Walsh CE et al. Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector. J Clin Invest 1994; 94: 1440-1448.
12. Walsh CE et al. Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector. Proc Natl Acad Sci USA 1992; 89: 7257-7261.
13. Miller JL et al. Recombinant adeno-associated virus (rAAV)-mediated expression of a human gamma-globin gene in human progenitor-derived erythroid cells. Proc Natl Acad Sci USA 1994; 91: 10183-10187.
14. Zhou SZ et al. Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood. J Exp Med 1994; 179: 1867-1875.
15. Alexander IE, Russell DW, Miller AD. Transfer of contaminants in adeno-associated virus vector stocks can mimic transduction and lead to artifactual results. Hum Gene Ther 1997; 8: 1911-1920.
16. Matsushita T et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Therapy 1998; 5: 938-945.
17. Hargrove PW, Vanin EF, Kurtzman GJ, Nienhuis AW. High-level globin gene expression mediated by recombinant adeno-associated virus that contains the 3′ globin gene regulatory element and integrates as tandem copies in erythroid cells. Blood 1997; 89: 2167-2175.
18. Wang XS et al. Characterization of wild-type adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their elimination. J Virol 1998; 72: 5472-5480.
19. Snyder RO et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-276.
20. Zhou SZ et al. Adeno-associated virus 2-mediated gene transfer in murine hematopoietic progenitor cells. Exp Hematol 1993; 21: 928-933.
21. Bertran J et al. Recombinant adeno-associated virus-mediated high efficiency, transient expression of the murine cationic amino acid transporter (ecotropic retroviral receptor) permits stable transduction of human HeLa cells by ecotropic retroviral vectors. J Virol 1996; 70: 6759-6766.
22. Duan D et al. Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4 ORF6 and E2a gene expression. J Virol 1999; 73: 161-169.
23. Snyder RO et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nature Med 1999; 5: 64-70.
24. Herzog RW et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nature Med 1999; 5: 56-63.
25. Kaplitt MG et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994; 8: 148-154.
26. Malik P et al. Recombinant adeno-associated virus mediates a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line. J Virol 1997; 71: 1776-1783.
27. + cells. Hum Gene Ther 1998; 9: 2727-2734.
28. Chatterjee S et al. Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vectors. Blood 1999; 93: 1882-1894.
29. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.
30. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther 1998; 9: 2745-2760.
31. Salvetti A et al. Factors influencing recombinant adeno-associated virus production. Hum Gene Ther 1998; 9: 695-706.
32. Allen JM, Debelak DJ, Reynolds TC, Miller AD. Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production. J Virol 1997; 71: 6816-6822.
33. Clark KR, Liu X, McGrath JP, Johnson PR. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther 1999; 10: 1031-1039.
34. Zolotukhin S et al. Utilization of AAV receptor affinity to develop an efficient and novel purification protocol for vector production. Gene Therapy 1999; 6: 973-985.
35. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438-1445.
36. + hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation. J Virol 1997; 71: 8262-8267.
37. Sitnicka E et al. Transforming growth factor beta 1 directly and reversibly inhibits the initial cell divisions of long-term repopulating hematopoietic stem cells. Blood 1996; 88: 82-88.
38. Cashman JD, Eaves CJ, Sarris AH, Eaves AC. MCP-1, not MIP-1alpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood 1998; 92: 2338-2344.
39. Murphy M, Perussia B, Trinchieri G. Effects of recombinant tumor necrosis factor, lymphotoxin, and immune interferon on proliferation and differentiation of enriched hematopoietic precursor cells. Exp Hematol 1988; 16: 131-138.
40. + cells. Br J Haematol 1998; 101: 756-765.
41. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 1992; 158: 97-129.
42. Halbert CL, Standaert TA, Wilson CB, Miller AD. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J Virol 1998; 72: 9795-9805.
43. Manning WC et al. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum Gene Ther 1998; 9: 477-485.
44. Halbert CL et al. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J Virol 1997; 71: 5932-5941.
45. Koeberl DD et al. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci USA 1997; 94: 1426-1431.
46. Fisher KJ et al. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996; 70: 520-532.
47. Russell DW, Alexander IE, Miller AD. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci USA 1995; 92: 5719-5723.
48. Summerford C, Bartlett JS, Samulski RJ. αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nature Med 1999; 5: 78-82.
49. Huang S, Endo RI, Nemerow GR. Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol 1995; 69: 2257-2263.
50. Mah C et al. Adeno-associated virus type 2-mediated gene transfer: role of epidermal growth factor receptor protein tyrosine kinase in transgene expression. J Virol 1998; 72: 9835-9843.
51. Fietze E et al. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation 1994; 58: 675-680.
52. Laegreid A et al. Tumor necrosis factor induces lipopolysaccharide tolerance in a human adenocarcinoma cell line mainly through the TNF p55 receptor. J Biol Chem 1995; 270: 25418-25425.
53. Civin Cl et al. Sustained, retransplantable, multilineage engraftment of highly purified adult human bone marrow stem cells in vivo. Blood 1996; 88: 4102-4109.
54. Bhatia M et al. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci USA 1997; 94: 5320-5325.
55. Lubovy M et al. Stable transduction of recombinant adeno-associated virus into hematopoietic stem cells from normal and sickle cell patients. Biol Blood Marrow Transplant 1996; 2: 24-30.
56. Miao CH et al. The kinetics of rAAV integration in the liver. Nat Genet 1998; 19: 1913-1915.
57. Larochelle A et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nature Med 1996; 2: 1329-1337.
58. Persons DA et al. Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells. Nature Med 1998; 4: 1201-1205.
59. Samulski RJ, Chang LS, Shenk TE. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol 1987: 61: 3096-3101.
60. Albritton LM, Tseng L, Scadden D, Cunningham JM. A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection. Cell 1989; 57: 659-666.
61. Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989; 63: 3822-3828.
62. Srivastava A, Lusby EW, Berns KI. Neucleotide sequence and organization of adeno-associated virus 2 genome. J Virol 1983; 45: 555-564.